

Reviewer's code: 02439561

You did a great work to review on immunotherapy of gastroesophageal cancer just on time.

Reviewer's code: 03270428

In this review, the authors highlighted the clinical development of PD-1 inhibitors leading up to the recent approvals of pembrolizumab and nivolumab in advanced gastroesophageal cancer. In particular, they discussed preclinical rationale, early biomarker studies, and results currently available from major phase I-III trials investigating PD-1/PD-L1 inhibitors in advanced or metastatic gastroesophageal cancer. The manuscript is well written.

Reviewer's code: 03728442

Well-written, timely and topical review article on the challenge of biomarkers discovery in oncoimmunology. The authors comprehensively addressed and discussed all key points related to the development of immunotherapeutics in the field of gastroesophageal cancer as well as most promising predictive biomarkers in the pipeline.

Answer: There are no questions or concerns from reviewers to answer or address. Thanks for these positive comments.